Unlock instant, AI-driven research and patent intelligence for your innovation.

Sustained-release tramadol formulations with 24-hour efficacy

A tramadol and tablet technology, applied in the field of new oral pharmaceutical compositions, can solve the problems of inability to replace successfully

Inactive Publication Date: 2010-05-26
LABOPHARM INC +2
View PDF22 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Although there are some controlled-release formulations of tramadol HCl on the market that claim to be once-daily formulations, none of them have successfully replaced twice-daily formulations of tramadol HCl

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained-release tramadol formulations with 24-hour efficacy
  • Sustained-release tramadol formulations with 24-hour efficacy
  • Sustained-release tramadol formulations with 24-hour efficacy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] A. Cross-linking

[0109] High amylose (30.0 kg) containing about 70% w / w amylose (Cl AmyloGel 03003) was placed in the reactor. Water (55.0 l) containing sodium hydroxide (30.0 g) and sodium sulfate (2.40 kg) was added to the reactor. The resulting slurry was heated to a temperature of 30°C. Phosphorus oxychloride (22.5 g) was added to the reaction mixture and reacted for one hour.

[0110] B. Chemical Modification, Hydroxypropylation

[0111] The crude reaction mixture from Part A was transferred to the hydroxypropylation reactor. The reaction mixture was heated to a temperature of 40° C. for 30 minutes and purged with nitrogen. After complete termination, propylene oxide (1.80 kg) was added. The reaction mixture was kept at 40°C for 20 hours. with 0.1N H 2 SO 4 (1:2 v / v) to neutralize the reaction mixture to pH 5.5. The starch slurry was washed with a basket centrifuge at 1200 rpm. The resulting starch cake was reslurried in 35 l of water and centrifuged fo...

Embodiment 2

[0118] A. Cross-linking

[0119] High amylose (30.0 kg) containing about 70% w / w amylose (Cl AmyloGel 03003) was placed in the reactor. Into the reactor was charged water (55.0 1) containing sodium hydroxide (30.0 g) and sodium sulfate (2.40 kg). The resulting slurry was heated to a temperature of 30°C. Phosphorus oxychloride (45 g) was added to the reaction mixture and reacted for one hour.

[0120] B. Chemical Modification, Hydroxypropylation

[0121] The crude reaction mixture from Part A was transferred to the hydroxypropylation reactor. The reaction mixture was heated to a temperature of 40°C for 30 minutes and quenched with nitrogen. After complete termination, propylene oxide (1.80 kg) was added. The reaction mixture was kept at 40°C for 20 hours. with 0.1N H 2 SO 4 (1:2 v / v) to neutralize the reaction mixture to pH 5.5. The starch slurry was washed with a basket centrifuge at 1200 rpm. The resulting starch cake was reslurried in 35 l of water and centrifuged ...

Embodiment 3

[0137] Formulations A, B and C shown in Table 1 were prepared according to the procedure given above.

[0138] Table 1: Formulations of tramadol hydrochloride controlled release formulations A, B and C.

[0139]

[0140]

[0141] figure 2 Dissolution profiles for Formulations A, B and C are shown.

[0142] once-daily formulation of tramadol

[0143] The present invention relates to controlled release tablet compositions which provide analgesia within 2 hours of oral administration and for at least 24 hours after administration.

[0144] A 200 mg dose of the controlled release composition of the present invention surprisingly provides rapid analgesic effect within 2 hours after oral administration, with mean blood levels ranging from 100 ng / mL to 200 ng / mL for at least 24 hours after administration of a single dose between.

[0145] Furthermore, at steady state, mean tramadol plasma concentrations range between 100 ng / mL and 350 ng / mL. The controlled release composi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration.

Description

technical field [0001] The present invention relates to novel once-daily oral pharmaceutical compositions for controlled release tramadol or a salt thereof. Background technique [0002] Tramadol Pharmaceutical Preparations [0003] Tramadol hydrochloride (HCl) was developed by Grünenthal GmbH, Germany. Available in Germany since 1977 (e.g. Tramal TM ), since 1995 with Listed in the US. The efficacy and safety of tramadol HCl make it ideal for long-term treatment of chronic pain. [0004] Tramadol HCl is a synthetic centrally acting analgesic that has shown effectiveness in a number of acute and chronic pain states. In particular, tramadol HCl in immediate and delayed release formulations in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) (Roth SH. "Tramadol HCl in rebound musculoskeletal pain caused by osteoarthritis." Efficacy and safety". J. Rheumatol 1998;25:1358-1363. Wilder-Smith CH et al., "Treatment of osteoarthritis-derived Severe pain in pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/20
Inventor 文森特·莱纳尔特斯帕特里夏·洛尔·奥尔德基·恩吉基乔纳森·培根拉奇德·奥泽阿罗索尼娅·简维斯米卢德·拉赫毛尼戴蒙·史密斯
Owner LABOPHARM INC